Stryker Corporation (SYK)

NYSE: SYK · USD

—

영어 원본으로 대체KO

번역하는 동안 영어 원본을 표시 중

이 리포트는 아직 번역되지 않았습니다. 번역 대기열이 따라잡으면 몇 분 후에 새로고침하세요.

StockMarketAgent Research · Analyzed 2026-10-22

Our latest published analysis: SYK rated Hold

Stryker Corporation's published Hold conclusion compares the analysis-date price with fair value and potential value. Read the full report for assumptions, evidence, and material risks.

Fair value

$313 / share

Potential value

$413 / share

Upside to FV

+5.2%

Moat

8.5/10

Narrow

Read full analysis →View archive · 24mo

9-phase methodology · same model in each published edition

Market cap	$114.2B
P/E (forward)	16.5x

Market data

Price

Recent price action with selectable time range.

Financial snapshot

P/E (forward): 16.5x
Market cap: $114.2B

Item	P1	P2	P3	P4	P5	Trend
Period	2021-12-31	2022-12-31	2023-12-31	2024-12-31	2025-12-31	Trend
Revenue	$17.11B	$18.45B	$20.50B	$22.60B	$25.12B	+10.1%
Gross profit	$10.97B	$11.58B	$13.06B	$14.44B	$16.07B	+10.0%
Operating income	$2.58B	$2.84B	$3.89B	$3.69B	$4.89B	+17.3%
Net income	$1.99B	$2.36B	$3.17B	$2.99B	$3.25B	+13.0%
EPS (diluted)	$5.21	$6.17	$8.25	$7.76	$8.40	+12.7%
EBITDA	$3.61B	$4.02B	$5.06B	$6.01B	$6.31B	+15.0%
R&D	$1.24B	$1.45B	$1.39B	$1.47B	$1.62B	+7.1%
SG&A	$6.43B	$6.39B	$7.11B	$7.69B	$8.65B	+7.7%

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
AAPL	Apple Inc.	—	—	—	—	—	—	매도
ABNB	Airbnb, Inc.	—	—	—	—	—	—	매도
ADBE	Adobe Inc.	—	—	—	—	—	—	적극 매수
ABBV	AbbVie Inc.	—	—	—	—	—	—	매도
ABT	Abbott Laboratories	—	—	—	—	—	—	비중 축소
ALGN	Align Technology Inc.	—	—	—	—	—	—	비중 축소

Base and Bull scenarios

Bull20%

Price target

$413.44

+38.9% from spot

Accelerated hospital capital equipment spending, record Mako robotic placements in hospital and ASC settings, and rapid clearance of Peripheral Vascular backorders drive double-digit earnings compounding and accelerated operating margin expansion ahead of house expectations.

EPS annual compound growth of 12.5% through explicit forecast horizon.
Adjusted operating margin expands beyond 21.2% ahead of schedule.
Rapid ASC robotic placement acceleration and sustained procedure volume expansion.

Base55%

Price target

$313.18

+5.2% from spot

Stryker executes within its guided organic sales growth corridors, transitioning to steady high-single-digit revenue expansion through FY2030 supported by resilient reconstructive procedure volumes and steady operating margin progression.

FY2026 revenue of $27.17B and adjusted EPS of $14.95.
FY2027 revenue of $29.49B and adjusted EPS of $16.66.
Operating margin expands from 19.5% in FY2026 to 21.2% in FY2030.
Terminal exit P/E multiple of 18.0x and perpetual growth rate of 3.0%.

Sensitivity: Ke × terminal growth

The highlighted cell is Fair value when every assumption sits at its base level ($313.18). Each row and column shows what Fair value becomes when one assumption moves.

Ke ↓ / g →	2.5%	2.8%	3.0%	3.3%	3.5%
7.6%	$346	$357	$368	$381	$395
8.1%	$321	$329	$338	$348	$359
8.6%	$299	$306	$313	$321	$330
9.1%	$280	$286	$292	$299	$306
9.6%	$264	$269	$274	$279	$285

Scorecard

Published factor rows and weighted composite

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector percentile context

Forward P/E16.5

P25 n/aP50 n/aP75 n/a

Trailing P/E31.5

P25 n/aP50 n/aP75 n/a

ROEn/a

P25 n/aP50 n/aP75 n/a

ROICn/a

P25 n/aP50 n/aP75 n/a

Benchmarks · 1M

Deeper analysis on SYK

14 sections in the full report · jump straight to what you need

Forecast

Base and Bull forecast paths with report-date return framing.

→

Valuation

Fair-value bridge, DCF, owner earnings, and peer multiples.

→

Sensitivity

Cost-of-equity and terminal-growth stress table.

→

Risks

Kill scenarios, soft-pass flags, and downside catalysts.

→

Earnings

Next earnings setup and beat / inline / miss thresholds.

→

Position sizing

Entry, exit, conviction, and quarterly monitoring rules.

→

Financials

Revenue, margins, cash flow, and balance-sheet context.

→

Peers

Relative valuation and profitability against the cohort.

→

Moat

Economic-profit evidence and competitive advantage risk.

→

Industry cycle

Sector phase, capital cycle, and secular tailwinds.

→

Quote this valuation with its source: Fair value, Potential value and the price at analysis.

Frequently asked questions

About this SYK report

What is the latest published SYK stock rating?

Stryker Corporation is shown with Hold in the latest published report, analyzed 2026-10-22. The hub links directly to the full analysis surface where the dated rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full SYK analysis?

The full latest published report, analyzed 2026-10-22, lives at /stocks/SYK/analysis. The bare ticker page summarizes that read and links to each analysis tab; earlier editions remain under /analysis/archive.

What fair value is used for SYK?

The latest published report analyzed 2026-10-22 gives SYK a fair value of USD 313 and a potential value of USD 413. These are dated research outputs, not live market prices; review the valuation assumptions, sensitivity analysis, and material risks before making a decision.

How often is the SYK page updated?

The hub selects the latest published stock report regardless of age and displays its analysis date (2026-10-22). Separately sourced market data is labeled with its own recorded timestamp and is never inferred from the report.

HoldSYK · Fair value $313+5.2%

Read full analysis →

Category	Score	Reading
Valuation	6.0
Management	9.5
Balance Sheet	7.5
Profitability	6.5
Revenue Growth	6.0
Risk Assessment	8.0
Competitive Moat	8.5
Earnings Quality	9.0
Capital Efficiency	6.5

Stryker Corporation (SYK)

Our latest published analysis: SYK rated Hold

Price

Financial snapshot

Fair-value bridge

Latest news · SYK

Valuation

Base and Bull scenarios

Sensitivity: Ke × terminal growth

Scorecard

Next earnings

Sector percentile context

Deeper analysis on SYK

Frequently asked questions

등급 이력